{"id":"https://genegraph.clinicalgenome.org/r/060f1835-7c03-4cb2-b5c9-3b11a87c8eb4v2.0","type":"EvidenceStrengthAssertion","dc:description":"*GLT8D1* was first reported in relation to autosomal dominant amyotrophic lateral sclerosis in 2019 (Cooper-Knock J et al., PMID:30811981). At least 14 unique variants, including missense, synonymous and frameshift variants, have been reported in humans. Evidence supporting this gene-disease relationship includes case-level data and experimental data. \n\nVariants in this gene have been reported in 22 probands in 7 publications (PMID:30811981, 35525134, 34746377, 33714647, 31653410, 35873773, 33581933), but many were not scored in this curation due to a population frequency too high to be consistent with disease. \n\nThis gene-disease relationship has been studied in at least two case-control studies (PMID:30811981). An aggregate variant analysis of the* GLT8D1* exon 4 burden showed that when exon 4 is excluded from burden analysis, no significant association with ALS is found. The test only included variants which were present in <1/10,000 of ExAC. A single variant analysis association study of the R29C variant showed an odds ratio of 54, although w​​hen looking at patients carrying R92C without an ARPP21 variant the OR drops to 20.\n\nThis gene-disease relationship is also supported by an animal model and expression study. A zebrafish model demonstrated reduced movement of zebrafish after knockdown of endogenous *GLT8D1* and transfection of mutated version of *GLT8D1* (PMID:30811981). *GLT8D1* is expressed in central nervous system tissue (PMID:24309898), and a cellular model of GLT8D1 knock-down in neuronal stem cells which showed altered morphology of differentiated cells (PMID:29483533).\n\nThis gene-disease pair was originally evaluated by the Amyotrophic Lateral Sclerosis Spectrum Disorders GCEP on November 8, 2022. It was reevaluated on November 12, 2024. As a result of this reevaluation, the classification did not change. New evidence was added to the curation, one new case and two case-control studies, but it was not strong enough to change the curation. \n\nIn summary, there is limited evidence to support this gene-disease relationship. Although more evidence is needed to support a causal role, no convincing evidence has emerged that contradicts the gene-disease relationship. This classification was approved by the ClinGen Amyotrophic Lateral Sclerosis Spectrum Disorders GCEP on the meeting date January 14, 2025 (SOP Version 11).","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/060f1835-7c03-4cb2-b5c9-3b11a87c8eb4","GCISnapshot":"https://genegraph.clinicalgenome.org/r/a2c4f919-ccb5-4d9f-a604-5ed19e19057e","calculatedEvidenceStrength":"Limited","changes":[{"id":"cg:otherTextChange"},{"id":"cg:sopChange"},{"id":"cg:summaryChange"},{"id":"cg:newEvidence"}],"contributions":[{"id":"https://genegraph.clinicalgenome.org/r/a2c4f919-ccb5-4d9f-a604-5ed19e19057e_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10096","date":"2025-01-22T18:37:15.704Z","role":"Publisher"},{"id":"https://genegraph.clinicalgenome.org/r/a2c4f919-ccb5-4d9f-a604-5ed19e19057e_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10096","date":"2025-01-14T20:00:00.000Z","role":"Approver"}],"curationReasons":["RecurationNewEvidence"],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a2c4f919-ccb5-4d9f-a604-5ed19e19057e_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a2c4f919-ccb5-4d9f-a604-5ed19e19057e_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/efc43167-b1f8-4d00-81f6-50c84771c19b","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7a1efc17-efe6-45a8-9d2d-99f66f25ec71","type":"Finding","dc:description":"This is described in the human protein atlas https://www.proteinatlas.org/ENSG00000016864-GLT8D1/tissue/primary+data","dc:source":"https://pubmed.ncbi.nlm.nih.gov/24309898","rdfs:label":"GLT8D1_neuronal_cell_expression","demonstrates":{"id":"cg:GeneExpressionA"}}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/a2c4f919-ccb5-4d9f-a604-5ed19e19057e_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0b0887a8-8a82-47dd-b6fc-bc6f27ab9043","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0da29cbf-6e9f-408c-99e9-fb7fedb98f13","type":"Finding","dc:description":"Neurons in ALS are affected by altered morphology","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29483533","rdfs:label":"GLT8D1_KO_neuronal_stem_cells","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityCellCultureModelOrganismCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/83048935-1dae-4b55-87d5-4b315fbc0b96","type":"EvidenceLine","dc:description":"The observed phenotype is not an ALS phenotype so should not be scored.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/56a83629-22ce-4124-b2a3-2552bc80fa1a","type":"Finding","dc:description":"Both are phenotypes involving the nervous system. ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20562862","rdfs:label":"GLT8D1_mousemodel_exons1-6KO","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/fda9e83e-bc75-44c7-b7d5-8e07af3743bd","type":"EvidenceLine","dc:description":"Following scoring convention as per ALS GCEP guidance and through discussion agreed unclear whether the movement difference was considered a large difference in movement and whether the difference was definite due to altered motor neurons.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1a930529-5ea3-4442-bab7-da7ec17ebb31","type":"Finding","dc:description":"Movement is reduced in ALS","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30811981","rdfs:label":"GLTD81_zebrafish_model","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":1.5}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/a2c4f919-ccb5-4d9f-a604-5ed19e19057e_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/156e7ccf-bb9f-45b7-bb09-f4ebbb562f54","type":"EvidenceLine","dc:description":"Scored at 0.1 due to no evidence of loss of function contributing to disease and frameshift is at end of protein.","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/156e7ccf-bb9f-45b7-bb09-f4ebbb562f54_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31653410","allele":{"id":"https://genegraph.clinicalgenome.org/r/02ee67e3-8250-4b17-9380-ecfa50d4ca40","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_018446.4(GLT8D1):c.1106dup (p.Asn369LysfsTer30)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA2573331892"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/5c867df8-e251-4e67-a61a-6724b2261634","type":"EvidenceLine","dc:description":"Scored as an other variant due to lack of evidence supporting loss of function contributing to the disease phenotype.","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5c867df8-e251-4e67-a61a-6724b2261634_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/35873773","allele":{"id":"https://genegraph.clinicalgenome.org/r/78c368a5-1f5a-4beb-be76-5e06a12dfc4a","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_018446.4(GLT8D1):c.393del (p.Lys131AsnfsTer7)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA908134443"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/a2628ccb-11a2-4e6c-b0b1-1399ef4fc262","type":"EvidenceLine","dc:description":"gnomAD v2.1.1 non neuro minor allele frequency > 0.000005","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a2628ccb-11a2-4e6c-b0b1-1399ef4fc262_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33581933","allele":{"id":"https://genegraph.clinicalgenome.org/r/f4b11e5f-3149-4bba-8af5-56b8088ff004","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_018446.4(GLT8D1):c.233G>C (p.Gly78Ala)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA2445875"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/9ebe5b87-5cf6-46cd-8337-048b9d4347b4","type":"EvidenceLine","dc:description":"gnomAD v2.1.1 non neuro minor allele frequency > 0.000005","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/9ebe5b87-5cf6-46cd-8337-048b9d4347b4_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33581933","allele":{"id":"https://genegraph.clinicalgenome.org/r/c554c02d-4ebe-492c-a917-fcae5d875517","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_018446.4(GLT8D1):c.871G>A (p.Val291Ile)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA353154222"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/ee9ed4d7-0988-43c8-94a6-c3e5a98fa447","type":"EvidenceLine","dc:description":"gnomAD v2.1.1 non neuro minor allele frequency > 0.000005","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ee9ed4d7-0988-43c8-94a6-c3e5a98fa447_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33581933","allele":{"id":"https://genegraph.clinicalgenome.org/r/6ae44743-6155-4077-9838-976d9f9c2380","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_018446.4(GLT8D1):c.841G>A (p.Gly281Ser)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA2445669"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/1569e89f-79a7-441c-827e-8606ce485fcc","type":"EvidenceLine","dc:description":"MAF in gnomAD 2.1.1 non-neuro dataset >0.000005","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1569e89f-79a7-441c-827e-8606ce485fcc_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30811981","allele":{"id":"https://genegraph.clinicalgenome.org/r/85422ebf-3115-4e2c-a738-e9d7d00a9df9","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_018446.4(GLT8D1):c.274C>T (p.Arg92Cys)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA2445865"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/1569e89f-79a7-441c-827e-8606ce485fcc_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Overexpression of mutated GLTD81 increased cell cytotoxicity and reduced viability and glycosyltransferase activity in mutated proteins is reduced","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/fe5ee166-7522-4262-ad84-59e7c7f14d0e","type":"EvidenceLine","dc:description":"gnomAD v2.1.1 non neuro minor allele frequency > 0.000005","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/fe5ee166-7522-4262-ad84-59e7c7f14d0e_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33581933","allele":{"id":"https://genegraph.clinicalgenome.org/r/4d393e81-ba6d-4e11-9dc4-a9fb9f322654","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_018446.4(GLT8D1):c.71A>G (p.His24Arg)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA74794413"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/f23b4834-0a49-4ef3-ba97-cde8eee69883","type":"EvidenceLine","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f23b4834-0a49-4ef3-ba97-cde8eee69883_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/35525134","allele":{"id":"https://genegraph.clinicalgenome.org/r/d97a5f8d-838d-4178-b090-5e29b85c4cac","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_018446.4(GLT8D1):c.13A>G (p.Lys5Glu)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA353165550"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/0dfd601e-4a93-4cb9-9a99-4de464c8b14e","type":"EvidenceLine","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0dfd601e-4a93-4cb9-9a99-4de464c8b14e_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30811981","allele":{"id":"https://genegraph.clinicalgenome.org/r/90ce7545-4daa-4981-a33d-f3511b7ee026","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_018446.4(GLT8D1):c.260T>A (p.Ile87Asn)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA353163294"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/6e21e4f2-4b8a-44df-bf6b-c37dd841272f","type":"EvidenceLine","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6e21e4f2-4b8a-44df-bf6b-c37dd841272f_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30811981","allele":{"id":"https://genegraph.clinicalgenome.org/r/8f3b0573-e7ac-45b6-a379-812306c42c46","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_018446.4(GLT8D1):c.232G>T (p.Gly78Trp)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA2445876"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/2801d4bd-9bc2-49db-8d8c-f4949966e7c9","type":"EvidenceLine","dc:description":"MAF in gnomAD 2.1.1 non-neuro dataset >0.000005","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2801d4bd-9bc2-49db-8d8c-f4949966e7c9_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30811981","allele":{"id":"https://genegraph.clinicalgenome.org/r/85422ebf-3115-4e2c-a738-e9d7d00a9df9"},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/2801d4bd-9bc2-49db-8d8c-f4949966e7c9_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Overexpression of mutated GLTD81 increased cell cytotoxicity and reduced viability and glycosyltransferase activity in mutated proteins is reduced","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/4a6dcb1b-f9c3-484f-a038-7a57f04ac0d4","type":"EvidenceLine","dc:description":"gnomAD v2.1.1 non neuro minor allele frequency > 0.000005","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4a6dcb1b-f9c3-484f-a038-7a57f04ac0d4_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33581933","allele":{"id":"https://genegraph.clinicalgenome.org/r/4d393e81-ba6d-4e11-9dc4-a9fb9f322654"},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/ca8d9d52-bdd6-4503-b86b-5e4caafcc6ee","type":"EvidenceLine","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ca8d9d52-bdd6-4503-b86b-5e4caafcc6ee_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33714647","allele":{"id":"https://genegraph.clinicalgenome.org/r/d65b9451-d997-4271-9baf-93bc12af2c7f","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_018446.4(GLT8D1):c.948T>C (p.Tyr316=)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA353153405"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/67da470d-42e8-4e96-9a82-6c5391ba4973","type":"EvidenceLine","dc:description":"gnomAD v2.1.1 non neuro minor allele frequency > 0.000005","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/67da470d-42e8-4e96-9a82-6c5391ba4973_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30811981","allele":{"id":"https://genegraph.clinicalgenome.org/r/85422ebf-3115-4e2c-a738-e9d7d00a9df9"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/67da470d-42e8-4e96-9a82-6c5391ba4973_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Overexpression of mutated GLTD81 increased cell cytotoxicity and reduced viability and glycosyltransferase activity in mutated proteins is reduced","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/e4b06a63-585d-46fa-b0db-97714f92bba6","type":"EvidenceLine","dc:description":"Functional evidence was not consistent between cell types. ","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e4b06a63-585d-46fa-b0db-97714f92bba6_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30811981","allele":{"id":"https://genegraph.clinicalgenome.org/r/8f3b0573-e7ac-45b6-a379-812306c42c46"},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/e4b06a63-585d-46fa-b0db-97714f92bba6_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Overexpression of mutated GLTD81 increased cell cytotoxicity and reduced viability and glycosyltransferase activity in mutated proteins is reduced","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/cd7dae53-d56e-4805-b8d5-3afba0ff9388","type":"EvidenceLine","dc:description":"Protein was expressed in much higher concentrations than the other variants and cell viability and toxicity evidence was weak.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/cd7dae53-d56e-4805-b8d5-3afba0ff9388_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/34746377","allele":{"id":"https://genegraph.clinicalgenome.org/r/d55d3f6e-865b-4e65-9bc6-223ab799c69d","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_018446.4(GLT8D1):c.870C>G (p.Ile290Met)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA353154231"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/cd7dae53-d56e-4805-b8d5-3afba0ff9388_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Functional analyses show increased ER stress in HEK cells transfected with variant GLTD81 constructs and reduced glycosyltransferase activity","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/156cc0be-2d81-459e-a1dd-2abea5b41f96","type":"EvidenceLine","dc:description":"MAF in gnomAD 2.1.1 non-neuro dataset >0.000005","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/156cc0be-2d81-459e-a1dd-2abea5b41f96_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30811981","allele":{"id":"https://genegraph.clinicalgenome.org/r/85422ebf-3115-4e2c-a738-e9d7d00a9df9"},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/156cc0be-2d81-459e-a1dd-2abea5b41f96_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Overexpression of mutated GLTD81 increased cell cytotoxicity and reduced viability and glycosyltransferase activity in mutated proteins is reduced","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/67fea2e6-faa2-4aa7-bf36-b40671aa4571","type":"EvidenceLine","dc:description":"MAF in gnomAD 2.1.1 non-neuro dataset >0.000005","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/67fea2e6-faa2-4aa7-bf36-b40671aa4571_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30811981","allele":{"id":"https://genegraph.clinicalgenome.org/r/85422ebf-3115-4e2c-a738-e9d7d00a9df9"},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/67fea2e6-faa2-4aa7-bf36-b40671aa4571_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Overexpression of mutated GLTD81 increased cell cytotoxicity and reduced viability and glycosyltransferase activity in mutated proteins is reduced","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/a2c4f919-ccb5-4d9f-a604-5ed19e19057e_cc_el","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/62a14431-0b04-4309-87ef-1a0bdf62e123","type":"EvidenceLine","dc:description":"When exon 4 is excluded from burden analysis, no significant association with ALS is found. The test only included variants which were present in <1/10,000 of ExAC","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/62a14431-0b04-4309-87ef-1a0bdf62e123_cc_evidence_item","type":"Finding","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30811981","rdfs:label":"Exon 4 Burden Analysis","caseCohort":{"id":"https://genegraph.clinicalgenome.org/r/2c050d20-5a72-49ec-813d-c54228d21de8","type":"Cohort","allGenotypedSequenced":1138,"alleleFrequency":0.01142355008787346,"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/62a14431-0b04-4309-87ef-1a0bdf62e123_cc_evidence_item"}],"numWithVariant":13,"relatedCondition":{"id":"obo:MONDO_0004976"}},"controlCohort":{"id":"https://genegraph.clinicalgenome.org/r/ae4012a2-b3d4-4c42-ac00-4b7a849ab87e","type":"Cohort","allGenotypedSequenced":19450,"alleleFrequency":0.0007712082262210797,"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/62a14431-0b04-4309-87ef-1a0bdf62e123_cc_evidence_item"}],"numWithVariant":15},"method":{"id":"cg:AggregateVariantAnalysis"},"pValue":0.0025,"statisticalSignificanceType":"SKAT-O - Significantly enriched","statisticalSignificanceValueType":"Other"}],"specifiedBy":"GeneValidityCaseControlAggregateVariantAnalysisCriteria","strengthScore":0.25},{"id":"https://genegraph.clinicalgenome.org/r/da933418-47dc-4a8a-b439-52df7593a965","type":"EvidenceLine","dc:description":"Controls are not age matched which is relevant to this association study as age of onset in ALS patients is typically later due to being a progressive disease. However, all of the cases reported with the R29C variant have a relatively young age of onset. Controls are also not matched on genetic or ethnic background.\nWhen looking at patients carrying R92C without an ARPP21 variant the OR drops to 20. \nIt is assumed that the controls do not have an ARPP21 variant. ","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/da933418-47dc-4a8a-b439-52df7593a965_cc_evidence_item","type":"Finding","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30811981","rdfs:label":"Cooper-Knock et al Association Study","caseCohort":{"id":"https://genegraph.clinicalgenome.org/r/1a5383d7-3c3c-40ec-a22b-8351a13baa31","type":"Cohort","allGenotypedSequenced":4493,"alleleFrequency":0.001557979078566659,"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/da933418-47dc-4a8a-b439-52df7593a965_cc_evidence_item"}],"numWithVariant":7,"relatedCondition":{"id":"obo:MONDO_0004976"}},"controlCohort":{"id":"https://genegraph.clinicalgenome.org/r/7c35eb8c-c41c-4e0d-b89a-f7ebdf8bb5fe","type":"Cohort","allGenotypedSequenced":60706,"alleleFrequency":0.00003294567258590584,"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/da933418-47dc-4a8a-b439-52df7593a965_cc_evidence_item"}],"numWithVariant":2},"method":{"id":"cg:SingleVariantAnalysis"},"pValue":2.03E-8,"statisticalSignificanceType":"","statisticalSignificanceValue":54,"statisticalSignificanceValueType":"Odds Ratio"}],"specifiedBy":"GeneValidityCaseControlSingleVariantAnalysisCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallCaseControlEvidenceCriteria","strengthScore":1.25},{"id":"https://genegraph.clinicalgenome.org/r/5dcfc37d-1c30-4e61-b85c-ed3e241ec260","type":"EvidenceLine","dc:description":"gnomAD v2.1.1 non neuro minor allele frequency > 0.000005","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5dcfc37d-1c30-4e61-b85c-ed3e241ec260_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33581933","allele":{"id":"https://genegraph.clinicalgenome.org/r/7a9ff0e5-99cb-4c55-b07a-34c321da14f6","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_018446.4(GLT8D1):c.764G>A (p.Arg255Gln)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA74789977"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/ea00a044-b4fe-44a4-bf50-cfa8a4512cfb","type":"EvidenceLine","dc:description":"MAF in gnomAD 2.1.1 non-neuro dataset >0.000005","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ea00a044-b4fe-44a4-bf50-cfa8a4512cfb_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30811981","allele":{"id":"https://genegraph.clinicalgenome.org/r/85422ebf-3115-4e2c-a738-e9d7d00a9df9"},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/ea00a044-b4fe-44a4-bf50-cfa8a4512cfb_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Overexpression of mutated GLTD81 increased cell cytotoxicity and reduced viability and glycosyltransferase activity in mutated proteins is reduced","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/a2c4f919-ccb5-4d9f-a604-5ed19e19057e_seg_el","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/548b7235-7cfb-45a4-bfc3-09c15b787911_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30811981","rdfs:label":"R92C_pedigree","estimatedLodScore":0.6,"family":{"id":"https://genegraph.clinicalgenome.org/r/548b7235-7cfb-45a4-bfc3-09c15b787911","type":"Family","rdfs:label":"R92C_pedigree","member":{"id":"https://genegraph.clinicalgenome.org/r/21b8b414-2f7f-42b0-82bc-b4d91a6cb4c3","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30811981","rdfs:label":"R92C_proband","allele":{"id":"https://genegraph.clinicalgenome.org/r/85422ebf-3115-4e2c-a738-e9d7d00a9df9"},"previousTesting":true,"previousTestingDescription":"Screening for ALS associated mutations in SOD1, C9ORF72, TARDBP, and FUS;","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/67da470d-42e8-4e96-9a82-6c5391ba4973_variant_evidence_item"}}},"meetsInclusionCriteria":false,"phenotypeNegativeAlleleNegative":6,"phenotypePositiveAllelePositive":2,"proband":{"id":"https://genegraph.clinicalgenome.org/r/21b8b414-2f7f-42b0-82bc-b4d91a6cb4c3"}}],"specifiedBy":"GeneValiditySegregationEvidenceCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/b2cdc0d4-dc54-4ab9-bd7f-168e8b9bac39","type":"EvidenceLine","dc:description":"MAF in gnomAD 2.1.1 non-neuro dataset >0.000005","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b2cdc0d4-dc54-4ab9-bd7f-168e8b9bac39_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30811981","allele":{"id":"https://genegraph.clinicalgenome.org/r/85422ebf-3115-4e2c-a738-e9d7d00a9df9"},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/b2cdc0d4-dc54-4ab9-bd7f-168e8b9bac39_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Overexpression of mutated GLTD81 increased cell cytotoxicity and reduced viability and glycosyltransferase activity in mutated proteins is reduced","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/ce3b2717-9024-497a-a25a-1ec7c9b93669","type":"EvidenceLine","dc:description":"MAF in gnomAD 2.1.1 non-neuro dataset >0.000005","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ce3b2717-9024-497a-a25a-1ec7c9b93669_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30811981","allele":{"id":"https://genegraph.clinicalgenome.org/r/85422ebf-3115-4e2c-a738-e9d7d00a9df9"},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/ce3b2717-9024-497a-a25a-1ec7c9b93669_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Overexpression of mutated GLTD81 increased cell cytotoxicity and reduced viability and glycosyltransferase activity in mutated proteins is reduced","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/8cd889f6-6930-4762-ac42-4574eba77f06","type":"EvidenceLine","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/8cd889f6-6930-4762-ac42-4574eba77f06_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30811981","allele":{"id":"https://genegraph.clinicalgenome.org/r/056aa4d1-b0de-489f-ba3d-12b3ba5e8b91","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_018446.4(GLT8D1):c.245C>A (p.Ala82Glu)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA2445868"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/c40892b9-5ac3-48d0-9c56-675ec53f3a7d","type":"EvidenceLine","dc:description":"MAF in gnomAD 2.1.1 non-neuro dataset >0.000005","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c40892b9-5ac3-48d0-9c56-675ec53f3a7d_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30811981","allele":{"id":"https://genegraph.clinicalgenome.org/r/85422ebf-3115-4e2c-a738-e9d7d00a9df9"},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/c40892b9-5ac3-48d0-9c56-675ec53f3a7d_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Overexpression of mutated GLTD81 increased cell cytotoxicity and reduced viability and glycosyltransferase activity in mutated proteins is reduced","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":2.15}],"evidenceStrength":"Limited","sequence":9849,"specifiedBy":"GeneValidityCriteria11","strengthScore":4.15,"subject":{"id":"https://genegraph.clinicalgenome.org/r/aA7pcEOl4tQ","type":"GeneValidityProposition","disease":"obo:MONDO_0004976","gene":"hgnc:24870","modeOfInheritance":"obo:HP_0000006"},"version":"2.0","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_a2c4f919-ccb5-4d9f-a604-5ed19e19057e-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}